CA-CROWN-BIOSCIENCE
5.1.2023 21:01:34 CET | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO), and JSR Life Sciences company, announced today their newly published study in PLOS ONE, a journal of the Public Library of Science (PLOS), demonstrating the establishment and application of a highly clinically relevant 3D in vitro PDX-derived organoid (PDXO) biobank for higher-throughput screening for cancer drug discovery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005843/en/
Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience (Photo: Business Wire)
This study aligns well with the recent Senate Bill 5002, titled FDA Modernization Act 2.0, introduced in the United States Senate, which authorizes the use of alternatives to animal testing, including cell-based assays for the purposes of drug and biological product applications.
“This invaluable publication demonstrates our ongoing commitment to develop innovative preclinical models for our customers by including the provision of robust and clinically relevant in vitro solutions as early as possible in the drug development process followed with matched translational models downstream,” commented Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience. “Organoids maintain a high degree of clinical relevance that cannot be achieved with traditional 2D cell lines and other 3D systems. As a result, in vitro drug screening with PDXOs represents a highly physiologically relevant platform that better predicts patient response making these ideal alternatives to animal testing.”
This new study reports on the largest living, commercially available PDXO biobank—with approximately 550 tumor organoid models derived from a collection of matched PDXs representing 17 different types of carcinomas. The main findings of the study include:
- The biological equivalence and interchangeability between PDXOs and parental PDXs were confirmed based on genomics, histopathology, and pharmacology.
- PDXOs in 384-well format assays are reliable, robust, and suitable for higher-throughput screening for rapid identification of drug sensitivity and drug combination strategies, including for matrix screening, encompassing both lead compounds and indications.
- PDXOs are amenable to engineering, such as gene editing to significantly broaden large-scale research applications, including in vitro/in vivo imaging analysis.
- The successful co-culture of PDXOs with PBMCs and CAR-T cells to investigate immune modulation and tumor killing.
This large biobank provides a unique collection of matched in vitro and in vivo preclinical patient-derived models which can be accessed via Crown Bioscience’s online databases OrganoidBase™ and HuBase™. This powerful translational tool has distinct advantages over other systems such as providing higher throughput with faster results as compared to in vivo models alone, with robust and renewable assay performance that reflects reproducibility of other in vitro systems. In vitro drug screening with PDXOs can rapidly be integrated into early drug development and interchangeably with translational studies and improved predictions of clinical outcome.
To read the full publication entitled “A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology”, follow this link.
###
About Crown Bioscience
Crown Bioscience is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). Crown Bioscience is the exclusive preclinical CRO to offer tumor organoid services, utilizing Hubrecht Organoid Technology (HUB) to establish 3D in vitro tumor organoids that have been shown to faithfully recapitulate the phenotypic and genetic features of their original tumor, and these models are playing an increasingly important role in cancer drug discovery, particularly in identifying anticancer agents with improved translational potential. In addition, Crown Bioscience has developed OrganoidBase™, an extensive searchable biobank consisting of hundreds of PDXO models with information on histopathology, IC50, and genomic and transcriptomic analysis data associated with drug response. Crown Bioscience is focused on helping our customers develop novel therapies to help patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities across the US, Europe, and Asia.
For more information or to get in touch, please visit: www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005843/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
